论文部分内容阅读
本试验采用ELLSA法检测了60例口腔颌面部恶性肿瘤病人，21例口腔颌面部良性肿瘤病人，30例正常人的sIL－2R水平。结果：恶性肿瘤病人sIL－ZR水平较良性肿瘤病人较正常人水平明显升高（P＜0．001），良性肿瘤病人与正常人间无差异（P＞0.05），且sIL－2R水平与病理分级及临床分期有关。sIL－2R作为监视机体免疫状态的一种指标可帮助诊断分析、病情监测及预后评估。
In this study, 60 patients with malignant tumors of oral and maxillofacial region, 21 patients with benign tumor of oral and maxillofacial region and 30 normal individuals were tested for the level of sIL-2R by ELLSA. Results: The level of sIL-ZR in patients with malignant tumors was significantly higher than that in benign tumors (P <0.001), there was no difference between benign tumor patients and normal subjects (P> 0.05), and the level of sIL-2R and pathological grade And clinical stage related. sIL-2R as an indicator of the immune status of the body can help diagnose, monitor and assess prognosis.